Nudging Physicians and Patients With Autopend Clinical Decision Support to Improve Diabetes Management
Laura Panattoni, PhD; Albert Chan, MD, MS; Yan Yang, PhD; Cliff Olson, MBA; and Ming Tai-Seale, PhD, MPH
The timely completion of routine preventive care is critical for diabetes management, yet only 39.5% of US patients diagnosed with diabetes have received all guideline-recommended services.1,2
Stage II of the Meaningful Use legislation, Medicare’s Electronic Health Record (EHR) Incentive Program, requires the use of clinical decision support (CDS) to remind patients about preventive care. However, Medicare states that there is no definitive or comprehensive list of what constitutes CDS, partly to encourage the creation of novel and innovative CDS tools.3
Various CDS systems have been developed to improve the completion of routine preventive diabetes care. The use of electronic reminders to providers, often in the patient’s chart, prompts limited improvement,4-6
partly because providers respond 30% to 40% of the time.7,8
Study results have shown that electronic reminders sent directly to patients improve diabetes management.9,10
However, a randomized controlled trial involving electronic alerts to both patients and providers had mixed findings.11
This suggests that the interaction between patient and clinician interventions within CDS may be critical, especially if these systems developed independently.
The provider–patient interface can inadvertently generate barriers to preventive care. Providers are required to review and authorize each laboratory order, even if they occur routinely. Providers and patients may fail to perform required tasks (eg, authorization or laboratory test completion) without prompting.12
However, locating provider alerts in the patient’s chart contributes to alert fatigue and creates challenges for patient management between visits.8
When patient alerts are triggered independently of the clinician authorization, patients may need to complete additional burdensome steps to confirm the laboratory order’s authorization, such as checking with the provider’s office, the laboratory, or additional websites.
Health information technology leaders at Sutter Health, a large nonprofit integrated healthcare delivery system headquartered in Sacramento, California, designed and incorporated an autopend functionality into the CDS. Autopend aimed to nudge providers and patients by simplifying workflow, removing barriers, and coordinating actions to improve preventive care. We examined whether incorporating an autopend functionality improved the likelihood of routine glycated hemoglobin (A1C) laboratory test completion for patients with diabetes.
RESEARCH DESIGN AND METHODS
The study was conducted at the Palo Alto Medical Foundation (PAMF), an affiliate of Sutter Health. PAMF is an ambulatory healthcare system serving more than 1 million patients in northern California. It has used a fully integrated EpicCare EHR with electronic health maintenance topic (HMT) patient reminders since 1999. The autopend functionality was activated on November 13, 2012.
We conducted an observational pre-post study at the HMT reminder level and tracked associated A1C laboratory test completion. We compared HMT reminders sent in the year before autopend (November 1, 2011-November 13, 2012) with those in the 1.5 years after (November 13, 2012-June 30, 2014). Our data recorded laboratory test completion for an additional 6 months (through December 2014). We included all HMT reminders sent to patients eligible for autopend, who were defined as those with a problem list diagnosis of diabetes mellitus (International Classification of Diseases, Ninth Revision
codes 250.xx, 401.xx, 790.xx, 272.xx, 791.xx, 790.29), a designated primary care provider (PCP), and an activated patient portal (MyHealthOnline). A total of 8792 patients received 15,630 HMT reminders.
Autopend Functionality and the HMT System
HMT reminders were sent to patients independently of providers’ authorization. All HMT reminders included “usual” content, which stated “you are due for” an A1C test and instructed patients to check a website to see if their laboratory tests had been ordered. If not, patients had to contact their provider. The CDS included provider alerts only in the patient’s chart. Providers learned about upcoming laboratory tests either when contacted by a patient or if they opened the patient’s chart, perhaps during an office visit. The provider then reviewed the order, filled out the authorization form, and contacted the patient.
Autopend (1) routed upcoming laboratory test notifications to a separate electronic folder, in addition to including an alert in the patient’s chart; (2) automatically populated or “pended” preauthorization forms in the electronic folder; and (3) linked the timing and content of the patient HMT reminders to the provider authorization. If the provider approved the order, an HMT reminder with autopend content was sent to patients stating “your clinician has ordered” an A1C test and they could proceed directly to the laboratory. In this case, the patient could skip checking the website and potentially following up with their provider. If the provider declined or ignored the notification, an HMT reminder with usual content was sent and patients had to complete the additional steps (eAppendices A
, and C
[eAppendices available at ajmc.com
] provide further description).
EHR data were combined with HMT metadata. We used a structured text mining process to categorize patient HMT reminders according to autopend and usual content.
Patient HMT reminders.
“Post autopend” indicated all HMT reminders sent after November 13, 2012. “Read reminder” recorded whether the patient clicked on the HMT reminder. “Time to reading” measured the number of days between when the HMT reminder was sent and when the patient clicked on it.
Time to laboratory test completion.
This measured the number of days between when the HMT reminder was sent and laboratory test completion.
We examined unadjusted differences in patient, provider, and HMT reminder characteristics for reminders sent in the preautopend and postautopend periods. P
values were calculated based on the results of χ2
tests, and nonparametric equality of medians tests.
A Cox proportional hazard model13
was used to estimate the likelihood of laboratory test completion based on 3 HMT reminder characteristics: preautopend versus postautopend period, read versus unread, and time to reading. The model adjusted for patient’s sex, self-reported race/ethnicity, age, insurance type, and Charlson Comorbidity Index score,14
along with the sex and specialty of the patient’s PCP. We addressed missing data in the explanatory variables by including a category for unknown. To account for repeated HMT reminders within patients, we clustered standard errors at the patient level. We included quarter fixed effects to control for secular trends. Schoenfeld tests rejected the proportional hazards assumption, so we added time-varying covariates with a natural log of time specification.13
We used the STCOX and LINCOM procedures in Stata 13.1 (StataCorp LP; College Station, Texas) and reported estimates in hazard ratios (HRs).15
In the period before autopend, 6329 HMT reminders were sent to 5197 patients (Table 1
). Patients who received reminders in the preautopend period had an average age of 59 years and were primarily male (58.7%) and mainly white (46.6%) or Asian (30.9%); almost half (48.5%) were insured by a preferred provider organization. In comparison, patients who received reminders in the postautopend period were more likely to have Medicare fee-for-service or unknown insurance (P
<.001) and a female PCP in family medicine (P
In the preautopend period, all HMT reminders had usual content. Most reminders (85.2%) were read by the end of the study period (Table 1). However, the median time to reading was 3 days, and 75% of the reminders were read within 38 days. Most of the laboratory tests associated with the reminders (81.2%) were completed by the end of the study period. The median time to completion was 48 days, with 75% of the laboratory tests completed within 106 days.
In the postautopend period, 87.0% of the HMT reminders included autopend content, reflecting the proportion of autopended orders approved by the PCPs, whereas 13.0% included usual content, which resulted from rejected orders. HMT reminders in the postautopend period were read slightly sooner than those in the preautopend period (median time to reading, 1 day vs 3 days; P
<.001) (Table 1). eAppendix D
illustrates that in the first 2 months after a reminder was sent, reminders with either autopend or usual content sent in the postautopend period were slightly more likely to be read than reminders sent in the preautopend period. The median time to laboratory test completion was also 8 days shorter in the postautopend period (40 days vs 48 days; P
<.001) (Table 1; eAppendix E
). eAppendix D illustrates that 2 months after the reminder was sent, read reminders with autopend content were associated with higher rates of laboratory test completion (59.5%) than read reminders with usual content in either the preautopend period (52.2%) or the postautopend period (42.2%; P
Next, we compared the adjusted effect of receiving an HMT reminder in the postautopend period for read and unread reminders (Table 2
). Comparing reminders read on the same day they were sent (time to reading, 0 days), reminders sent in the postautopend period were associated with a 33.9% increase in the likelihood of laboratory test completion (HR, 1.339; P
<.01). However, for reminders read 60 days after being sent, this increase in likelihood was lower, at 20.4% (P
= .055). The improvement in the likelihood of an A1C laboratory test being completed in the postautopend period remained significant (HR, 1.211; P
= .050) for reminders read up to 57 days after being sent, which included 68.4% of all reminders. For unread reminders, there was no statistically significant difference in A1C laboratory test completion among patients who were sent reminders in the postautopend period.
We also compared the adjusted effect of reading an HMT reminder in the preautopend and postautopend periods (Table 2). In the preautopend period, a read reminder was associated with a 76.7% increase in the likelihood of laboratory test completion (HR, 1.767; P
<.001; time to reading, 0 days) compared with an unread reminder. However, in the postautopend period, a similar read reminder was associated with a 143.1% increase in likelihood of completion (HR, 2.431; P
<.001; time to reading, 0 days).
We evaluated the impact of incorporating a novel autopend functionality into the CDS on routine A1C laboratory test completion. We found that for HMT reminders read within 57 days, reminders sent in the postautopend period were associated with a 21.1% (HR, 1.211; P
= .050) to 33.9% (HR, 1.339; P
= .003) increase in the likelihood of laboratory test completion. This result included 68% of the HMT reminders. However, the likelihood of laboratory test completion decreased the longer it took the patient to read the reminder. Among unread reminders, we found no statistical difference in A1C laboratory test completion in the postautopend period.
The autopend design was guided by the behavioral economics principle of nudging people to do the right thing. Autopend allowed the majority of patients to skip checking an additional website and potentially contacting their provider to check the laboratory test’s authorization status. Relocating provider triggers from the patient’s chart to a separate electronic folder for providers to approve, as well as coordinating the timing and content of the patient reminders with the provider authorization, may have minimized alert fatigue,16
the electronic task demand (eg, clicks, data entry, and time), and the downstream actions required by both parties. This in turn may have reduced providers’ workflow interruption and cognitive burden, improving job performance and satisfaction.17,18
However, the effects of these design features were associated with diminishing improvements for patients who took longer to read their reminders.
Although 87.0% of the postautopend period HMT reminders had autopend content, caution should be exercised before concluding that laboratory test completion rates could have been higher had all patients received autopend content. Patient and provider characteristics associated with the usual-content HMT reminders, and not the actual reminder content, may have contributed to the lower rates. Future research should explore these factors and the CDS designs that address them.
Stage II of the Meaningful Use criteria established expectations of using CDS to engage patients and improve population health.19
Although technology such as autopend may have an important role in helping health systems realize the potential of EHRs, physicians spend significant time meeting the demands of “desktop medicine.”20-22
Requiring physicians to approve autopend orders for regulatory compliance, rather than allowing them to go directly to patients or to the inboxes of other care team members, may have unintended consequences on physicians’ workflow. The functionality may need to be modified to enable other care team members to approve these orders.
This study has some limitations. The observational pre-post study design limits our ability to rule out confounding factors. However, we did statistically control for time trends through the use of quarter fixed effects. Secondly, this study took place in a single multispecialty delivery organization, which was an early adopter of EHRs, and autopend was added onto an existing EpicCare-specific HMT reminder system. Furthermore, this study included only patients with an active patient portal, limiting generalizability to other settings and patient populations. However, these principles of CDS design could be applied to other EHR systems.
Our study results suggest that incorporating an autopend functionality into a CDS system was associated with improvements in A1C laboratory test completion among patients with diabetes who read their HMT reminders in a timely fashion.
This multifaceted functionality was designed to simplify workflow, remove barriers, and coordinate the actions of patients and clinicians. Such a CDS tool can improve the care of chronically ill patients in the spirit of the Quadruple Aim.23